Navigation Links
CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
Date:4/8/2008

Study Supports CyberKnife's Clinical Flexibility, Expanding Physicians

Options for the Treatment of Prostate Cancer

SUNNYVALE, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that a study published in the April 1 issue of the International Journal of Radiation Oncology*Biology*Physics -- also known as the Red Journal -- demonstrates that the CyberKnife(R) Robotic Radiosurgery System can serve as a non-invasive means for delivering high dose rate (HDR) brachytherapy dosing. The study supports the CyberKnife System's clinical flexibility in treating prostate cancer and expands the non-invasive options available to clinicians and patients.

HDR brachytherapy has been shown to be an extremely effective approach for treating prostate cancer, with substantial clinical evidence supporting its usage. Nevertheless, the required insertion of multiple catheters into the prostate, where they remain for the duration of the procedure (typically 1-3 days), makes it an invasive procedure.

This study demonstrates the CyberKnife System's ability to non-invasively deliver complex HDR-like radiation dose sculpting to the prostate, without the need for hospitalization or anesthesia, maximizing patient comfort and convenience. Early clinical outcomes of the study show a rapid reduction in prostate specific antigen (PSA) levels with minimal short-term side effects.

"HDR brachytherapy is an effective, accepted treatment for prostate cancer, but adoption has been limited because it is a difficult procedure for clinicians to deliver and for patients to undergo," said Donald B. Fuller, M.D., radiation oncologist, CyberKnife
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
2. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
5. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
6. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
7. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...TLE, Nov. 19 Omeros Corp... financial results for the third quarter ended Sep...ber 30, 2009, Omeros reported a net loss of $3.9 m...oss of $7.4 million, or $2.54 per share, for the s...ember 30, 2009, the Company reported a net loss of...
(Date:11/19/2009)... ,, BETHESDA, Md., Nov. 19 /PRNewswire-FirstCa...nnovator in biotechnology for diabetes therapy, an...g services to food, supplement, biotechnology and ...d the previously reported $6.3 million registered ...60,870 shares of its common stock and warrants to ...
(Date:11/19/2009)...ESDA, Md., Nov. 19 Spher...biotechnology for diabetes therapy, and a provider...o food, supplement, biotechnology and pharmaceutic...ay,s Annual Meeting of Shareholders. ,, At the ...daq: SPEX ) elected the following members to the ...
(Date:11/19/2009)... MUNSTER, Germany, November 19 M...d on November 16th, 2009 Flibanserin in the,indica...a in Parkinson,s,disease for orphan drug status de...). Levodopa-induced dyskinesia is a complication o...nd a serious burden to some of those,affected, sin...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... Wis. - Pitney Bowes, a mail and document managem...cquire data-quality management company Firstlogic...stlogic,s outstanding shares, it was announced on ...nt ramifications of the deal won,t be known under ...s expected to close in the third calendar quarter ...
...is . -- Esker Software has added fax reception to ...r on Demand will be able to receive faxes directl...very service, Esker on Demand enables users of the...ng of their business documents. Users are invoiced... of inbound faxing, we have closed the loop to cre...
...is. - Startup entrepreneurs throughout the Upper ...ps about securing venture capital at the Wisconsi... at the Monona Terrace in Madison, will run from O...Technology Council, the Wisconsin Innovation Netwo...Entrepreneurs, Network. , ,"When you think about i...
Other Biology Technology:Pitney Bowes to acquire Firstlogic 2Conference will focus on financing of early-stage ventures 2Conference will focus on financing of early-stage ventures 3
(Date:11/20/2009)...earchers report that a class of heart medications ...l, effect on the heart, depending on their molecul...ournal Circulation Research , found that beta-blo...rs on the heart muscle offer the most benefit to c...beta-receptors can actually undermine the structur...
(Date:11/19/2009)...evealing the genetic instructions inside corn, one...s one of the most complex sequences of DNA ever an...icist David Schwartz, who was one of more than 100..., "The maize genome is a true maze full of conf...ld-be sequencers for years," says Schwartz. , Pu...
(Date:11/19/2009)...sity in maize, also known as corn, researchers acr...hat should pave the way to significant improvement... animal feed and fiber around the world. , The n...otype map, charts genetic diversity and recombinat... The research team, led by U.S. Department of Agri...
Breaking Biology News(10 mins):Carvedilol shown to have unique characteristics among beta blockers 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Substance Abuse Expert Dr Drew Joins Forces with the Five Moms to Raise Awareness About OTC Cough Medicine Abuse Among Teens 59825 1Substance Abuse Expert Dr Drew Joins Forces with the Five Moms to Raise Awareness About OTC Cough Medicine Abuse Among Teens 59825 2Substance Abuse Expert Dr Drew Joins Forces with the Five Moms to Raise Awareness About OTC Cough Medicine Abuse Among Teens 59825 3New Study Details Complex Health Care Needs of Medicaids Highest Need Highest Cost Populations 59821 1New Study Details Complex Health Care Needs of Medicaids Highest Need Highest Cost Populations 59821 2New Study Details Complex Health Care Needs of Medicaids Highest Need Highest Cost Populations 59821 3Celsis IVT Granted U S Patent for LiverPool 28TM 29 Hepatocytes 14543 1Celsis IVT Granted U S Patent for LiverPool 28TM 29 Hepatocytes 14543 2
...ears scientists have struggled to understand the d...e abundant and highly prized game and food fish na...poor marine survival is affecting salmon in the U....o determine in the ocean. Small acoustic tags and ... Thirty of 150 Atlantic salmon smolts tagged by N...
...NGTON, DCChildren,s National Medical Center immuno... Naynesh Kamani, MD , will serve as the study co-c...d donor marrow and umbilical cord blood transplant...tional will join more than 20 other medical instit...f this treatment. If successful, the Sickle Cell U...
...N, VA (August 18, 2008) Cocoa flavanols, the uniq...e blood flow to the brain, according to new resear...reatment journal. The researchers suggest that lon...ct cognitive behavior, offering future potential f...a and stroke. , ,In a scientific study of healthy,...
Other Biology News:Signals from the Atlantic salmon highway 2Signals from the Atlantic salmon highway 3Signals from the Atlantic salmon highway 4Children's national co-leads nationwide study of landmark sickle cell treatment 2Researchers link cocoa flavanols to improved brain blood flow 2Researchers link cocoa flavanols to improved brain blood flow 3
jetSI conc. 10 mM from Polyplus Transfection
...nsfection reagent that achieves over 90 % silencin...herent and primary cells with excellent cell viabi...ed toxic and off-target (non-specific) effects obs...ions, thereby allowing accurate and reliable silen...
...y Detection System uses biotin-avidin-HRP complexe...ary Antibody. The primary antibody binds to specif...tibody is removed by washing. Next, the Secondary ...nd will react with the primary antibody present on...
...s are intended for localization of antigens in a b...ns. These kits may be used with primary IgG antibo...r vendors. Briefly, detection is based on the form...ary antibodies that reacted with tissue antigens u...
Biology Products: